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OBJECTIVE — To evaluate the efﬁcacy of a removable cast walker compared with that of a
nonremovable ﬁberglass off-bearing cast in the treatment of diabetic plantar foot ulcer.
RESEARCH DESIGN AND METHODS — Forty-ﬁve adult diabetic patients with non-
ischemic, noninfected neuropathic plantar ulcer were randomly assigned for treatment with a
nonremovableﬁberglassoff-bearingcast(totalcontactcast[TCC]group)orwalkercast(Stabil-D
group).Treatmentdurationwas90days.Percentreductioninulcersurfaceareaandtotalhealing
rates were evaluated after treatment.
RESULTS — A total of 48 patients were screened; however, 2 patients in the TCC group and
1 patient in the Stabil-D group did not complete the study and were considered dropouts. There
were no signiﬁcant differences in demographic and clinic characteristics of the 45 patients
completing the study. Ulcer surface decreased from 1.41 to 0.21 cm
2 (P  0.001) in the TCC
group and from 2.18 to 0.45 cm
2 (P  0.001) in the Stabil-D group, with no signiﬁcant
differences between groups (P  0.722). Seventeen patients (73.9%) in the TCC group and 16
patients (72.7%) in the Stabil-D group achieved healing (P  0.794). Average healing time was
35.3  3.1 and 39.7  4.2 days in the TCC and Stabil-D group, respectively (P  0.708).
CONCLUSIONS — TheStabil-Dcastwalker,althoughremovable,wasequivalentinefﬁcacy
to the TCC in terms of ulcer size reduction and total healing rate. The easier use of Stabil-D may
help increase the use of off-loading devices in the management of plantar neuropathic diabetic
foot ulcers.
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T
he importance of excessive pressure
on the sole of the foot in the patho-
genesis of neuropathic plantar ul-
cers is well established (1). It is also
known that complete relief of pressure
from the ulcerated area is key to effective
healing (2). Use of a total contact cast
(TCC) is considered the gold standard for
management of neuropathic plantar ul-
cers(3).Nevertheless,managementofpa-
tients with a TCC poses several problems
(4). Proper TCC application with avoid-
ance of iatrogenic lesions requires skilled
cast technicians and is an expensive and
time-consuming process (5). The use of a
TCC is absolutely contraindicated in pa-
tientswithinfectionorcriticalischemia.A
TCC is also contraindicated in patients
who are very elderly, have visual or equi-
librium problems, have a contralateral
foot ulcer, or have varicose veins. For
these reasons, TCCs are rarely used (6).
In an attempt to overcome these
problems, recent studies have evaluated
the efﬁcacy of commercially available
nonremovable cast walkers (7–10). The
aim of this study was to evaluate healing
outcomes in diabetic patients managed
with a nonremovable TCC and a new re-
movable off-loading device speciﬁcally
designed for the management of neuro-
pathic plantar ulcers.
RESEARCH DESIGN AND
METHODS— Two centers specializ-
ing in diabetic foot management (located
in Sesto San Giovanni and Milan, Italy)
participated in this open, randomized
clinical trial. The ethics committee ap-
proved the study on 10 January 2008.
Consecutive patients were enrolled from
February 2008 through March 2009.
Studyinclusioncriteriawerethepresence
of a neuropathic plantar forefoot ulcer
with an area graded IA according to the
University of Texas Classiﬁcation of Dia-
betic Wounds (11). Peripheral neuropa-
thy was diagnosed based on insensitivity
to a 10-g Semmes-Weinstein monoﬁla-
ment in more than six of nine areas of the
footandbyavibrationperceptionthresh-
old measured by biothesiometer (Neu-
rothesiometer SLS, Nottingham, U.K.) at
themalleolusof25V.Exclusioncriteria
were the presence of an ankle-brachial
pressure index 0.9 and/or transcutane-
ousoxygentension50mmHgtestedon
thedorsumofthefootandclinicalsignsof
infection.Boththeprobe-to-bonemaneu-
verandstandardX-rayexaminationofthe
foot were required to be negative for os-
teomyelitis(12).Additionalexclusioncri-
teria included use of steroids or
antimitotic drugs, the presence of visual
problems that could impair balance, an
active ulcer on the contralateral foot, pre-
vious major amputation of the contralat-
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venous thrombosis of the leg, or mental
disorder interfering with patient
compliance.
Eligible patients were fully informed
of the study aim and procedures, and
written consent was obtained before
study participation. Patients were ran-
domly assigned to one of the two treat-
ment groups by opening randomization
codebreak envelopes containing one of
the two options. Separate randomization
wasperformedforeachcenter,andacopy
of all randomization envelopes was kept
at the statistical department of the Multi-
medica center. The two arms were com-
posed of patients managed with a
nonremovable ﬁberglass off-bearing cast
(TCC group) and patients managed with
the Stabil-D (Podartis, Montebelluna,
Treviso, Italy) walker cast (Stabil-D
group).
TCC— Patients in the TCC group were
casted according to the technique de-
scribed previously by Caravaggi et al.
(13). All casts were made by personnel
with particular expertise in the use of this
device (W.V. in Sesto San Giovanni and
D.S. in Milan). Two types of ﬁberglass
bandages were used for construction of
the pressure-relief apparatus. The ﬁrst
type of bandage (Softcast3M; 3M Health
Care, St. Paul, MN) was composed of ﬁ-
berglass imbued with a polyurethane
resinwithcharacteristicsofﬂexibilityand
resistance. The other bandage
(Scotchcast3M; 3M Health Care) was
composed of ﬁberglass imbued with a
polyurethane resin of two different con-
centrations that confers high resistance to
loading. A bandage with German cotton
and tubular stockinet was placed on the
limb. To further protect bony protru-
sions, such as the malleolus and tibial
crista, pieces of protective rubber foam
(Microfoam 3M; 3M Health Care) were
also applied. The structure was then rein-
forced with a stick made of a Scotchcast
bandage placed in the middle of the two
malleoli, extending beyond them for at
least20cmtogiverigiditytothecast.The
same material was used to build a rigid
plantarsole.Thenumberoflayersapplied
to construct the sole depended on the
weight of the patient (range 3–8 layers).
Analuminumstirrupwasanchoredtothe
structure as a support to allow walking.
The side supports were secured with an
outer layer of Softcast3M. After very brief
training, all patients were able to walk
properly without crutches.
Stabil-D
The Stabil-D device is composed of a spe-
ciﬁcally designed rigid, boat-shaped, and
fully rocker bottom sole: its rounded ex-
tremities (at the heel and tiptoe) facilitate
gait, and its middle section improves the
mid-stance phase. The insole height (24
mm) avoids excessive lifting of the con-
tralaterallimbduringwalk,thuslowering
the barycenter and favoring more stable
walking. The cover is made of Elastam
(Lycra),ayarncomposedofpolyurethane
segments and block copolymers that con-
fer high transparency and stability to the
system, mixed with polyethylene glycol
segments with the characteristic of elas-
ticity. At the ankle, the cast is provided
with removable, lateral stabilizer inserts
madeofABS,whichensurestabilitytothe
tibiotarsal joint and/or adequate support
during gait. Moreover, a rigid brace made
of a thermoformable polymer material
properly supports the Achilles tendon
and contributes to stability during rolling
steps; such a brace can be adapted to the
foot deformity using a hot air gun and
malleolar forceps. The cast is closed dor-
sally with Velcro wrap placed over the
forefoot to relieve skin pressure and Vel-
cro straps with self-ﬁtting rings placed
against the instep to secure perfect fasten-
ing, provide foot stability, and ensure a
perfect ﬁt of the heel in the rigid brace.
Finally, more Velcro straps are placed or
securedwithringsagainstthetibiatopro-
vide a secure ﬁt.
The cast has a special foot arch sup-
port (Modus) with small adaptable in-
serts. This modular insole is made of
multiple layers of different stiffness and is
speciﬁcally designed to allow proper off-
loading by removing the small inserts
from the ulcerated area, without the need
for traditional milling procedures. The
bottom layer is composed of chemically
knitted closed cell polyphenylic foam
(Evaform 167). The middle layer is com-
posed of knitted, expandable, and mold-
able closed cell polystyrene foam
(plastazole). The Diapod cover, speciﬁ-
cally designed for feet at risk of ulcer for-
mation, is composed of chemically
knitted dermocompatible Eva Diﬂex Vi-
bram (closed cell polyphenylic foam;
tested by ABICH Laboratories, Verbania,
Italy), which also has bactericidal and
fungicidal properties (tested by Fresenius
Institute, Taunusstein, Germany). Figure
1 shows the Stabil-D device and the Mo-
dus insole. Patients randomly assigned to
the Stabil-D group were carefully trained
for proper cast wearing, in particular for
accurate closure of Velcro straps, and
were prescribed continuous cast wear of
the Stabil-D; patients were allowed to re-
move the cast only during nocturnal rest.
Figure 1—“Stabil-D” device and the “Modus” insole. (A high-quality digital representation of this ﬁgure is available in the online issue.)
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Attheinitialvisit,ulcersweredebridedto
remove all nonviable tissue and to expose
the entire surface lesion. The ulcers were
thenphotographedandmeasuredusinga
Visitrak system (Smith & Nephew, Hull,
U.K.). Ulcers were dressed with parafﬁn
gauze and covered with sterile gauze be-
fore the application of the off-loading
device.
Follow-up
Patientswerefollowedweeklyfor90days
after application of the TCC or Stabil-D.
At each follow-up visit, off-loading de-
vices were removed, and dressings were
changed. The ulcer was photographed
and measured with the Visitrak system.
Afterward, patients in the TCC group
were provided with a newly manufac-
tured cast; patients in the Stabil-D group
had their cast walker and arch support
carefully controlled before reapplication
of the off-loading device.
End point
The primary end point was decrease in
ulcer size. The secondary end point was
rate of complete healing at study comple-
tion. Ulcers were considered healed if
they showed complete reepithelization of
the ulcerated area.
Statistical analysis
Homogeneity of the initial distribution of
baseline primary variables between
groupswastestedusingaFisherexacttest
for dichotomous variables and Student t
test for continuous variables. The differ-
ences in ulcer size reduction between the
two groups were compared using the
Mann-Whitney test. The Wilcoxon test
was used for analysis of ulcer size reduc-
tionovertimewithingroups.Healingrate
over time was analyzed by the Kaplan-
Meier test, and the log-rank test was used
to detect differences between the two
groups.
RESULTS— A total of 48 patients
were enrolled. Two patients in the TCC
group and one patient in the Stabil-D
group did not complete the study and
were considered dropouts. Of these three
dropout patients, one patient in the TCC
group withdrew consent, one patient in
the TCC group stopped treatment be-
cause of the development of an ulcer on
the contralateral foot, and one patient in
the Stabil-D group was unable to com-
plete the off-loading treatment because of
ulcer infection requiring antibiotic ther-
apyandmorefrequentclinicvisits.Ofthe
remaining45patientswhocompletedthe
study, there were 23 patients in the TCC
group and 22 patients in the Stabil-D
group. Table 1 reports demographic and
clinical characteristics of participants.
During the study some minor treat-
ment complications occurred, none of
which required cessation or change in
treatment. In the TCC group one patient
developed partial rupture of the stirrup,
whichwasreplacedwithoutremovingthe
cast. One patient showed hitching, which
resolved after removal of the German cot-
ton. One patient in the Stabil-D group
complained of odor and perilesional skin
maceration;however,thesewereresolved
at subsequent follow-up visits.
Ulcer surface area decreased from
1.41 to 0.21 cm
2 (P  0.001) in the TCC
group and from 2.18 to 0.45 cm
2 (P 
0.001)intheStabil-Dgroup;therewasno
signiﬁcant difference between groups
(P  0.72, Mann-Whitney test). The per-
cent reductions were 73.6 and 90.0% in
the TCC and Stabil-D groups, respec-
tively, with no statistically signiﬁcant dif-
ference between groups (P  0.321). The
time course of reduction in ulcer area did
not signiﬁcantly differ between the two
groups, as shown in Fig. 2 (P  0.721,
Wilcoxon test).
Seventeen patients (73.9%) in the
TCC group and 16 patients (72.7%) in
the Stabil-D group achieved complete
healing.Figure3showstheKaplan-Meier
estimate of complete healing rates at the
end of the study (P  0.794). The mean
duration of healing time was 35.3  3.1
day in the TCC group and 39.7  4.2
days in the Stabil-D group (P  0.708).
The average manufacturing time for
theTCCwas25min,andthetimeneeded
for cast removal using an oscillating cast
saw was 10 min. A very short period of
Figure 2—Ulcer size reduction at study completion. *Wilcoxon test. §Mann-Whitney test.
Table 1—Patient characteristics
TCC group Stabil-D group
P
value
n 23 22
Age (years) 59.0  8.5 61.7  10.4 0.35
Sex: female/male 8 (34.8)/15 (65.2) 7 (31.8)/15 (68.2) 0.83
Diet/insulin/oral therapy 4 (17.4)/16 (69.6)/3 (13.0) 5 (22.7)/10 (45.5)/7 (31.8) 0.21
Duration of diabetes (years) 17.7  11.2 17.2  10.7 0.88
BMI (kg/m
2) 32.3  4.5 30.3  1.1 0.16
A1C (% Hb) 9.1  2.1 7.5  1.1 0.18
Previous foot ulcer 15 (65.2) 15 (68.2) 0.82
Previous minor amputation 11 (47.8) 12 (54.5) 0.65
Mean area of lesion (cm
2) 1.4  1.2 2.2  2.2 0.47
Data are means  1S Do rn (%).
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tion the Stabil-D device.
The cost of the Stabil-D device was
€130eachplus€20fortheModusplantar
sole. The cost of the TCC was €73.50 per
cast (€22 for the stockinet, €4 for the Mi-
crofoam, and € 47.5 for the bandages).
For a very obese patient an extra bandage
was required, increasing the cost to
€89.5. Twenty-two off-loading devices
were applied to patients in the Stabil-D
group, and total costs were €3,300.00. A
total of 91 casts were applied to patients
in the TCC group for a total cost of
€6,688.50.
CONCLUSIONS — Among available
methodstorelieveplantarulcersresulting
from overpressure, the use of off-loading
casts, which can be fabricated in different
manners and with different materials, is
considered the gold standard (14,15).
However, it is well known that TCCs are
not widely used and that wheelchairs,
crutches, or therapeutic shoes with un-
loaded insoles are more commonly pre-
scribed in the management of patients
with plantar ulcers (16). What reasons
underlie these therapeutic choices? Cuta-
neous ulcers caused by friction of the cast
on bony protrusions are the most fre-
quent side effects from the use of rigid
casts (17). This problem could be solved
using materials whose rigidity can be
modulated; however, the whole proce-
dure for preparing such a type of TCC
requires signiﬁcant expertise and still re-
mains a costly and time-consuming pro-
cess. Another important issue is the high
percentage of patients, such as those with
vascular disease, bilateral ulcers, or lower
limb amputation, who cannot tolerate
TCCs (18).
The results of our study indicate that
the use of Stabil-D is as effective as use of
a TCC in the treatment of neuropathic
plantar forefoot ulcers. Similar results
were obtained in previous studies re-
ported by Piaggesi et al. (19) and Cara-
vaggi et al. (20); however, these two
reports differ from our study in two im-
portant ways.
First, Piaggesi et al. used a novel, off-
the-shelf nonremovable device, and we
used a removable cast. The efﬁcacy of
nonremovable off-loading devices has
been emphasized in previous studies.
Armstrong et al. (21) reported signiﬁcant
differences in the healing rates obtained
using removable or nonremovable cast
walkers. Katz et al. (22) found compara-
ble efﬁcacy of different types of equally
nonremovable cast walkers (22). Why we
obtained different results is uncertain. In
the literature, the superiority of nonre-
movable casts over removable ones is due
to poor patient compliance in the proper
use of an off-loading device (23,24). In
the two above-mentioned studies, the
percentage of patients with previous ul-
cers was not reported, suggesting that all
patientsenrolledpresentedwiththeirﬁrst
episode of ulcer. In our study population,
a high percentage of patients reported a
previousfootulcer,andahighpercentage
of patients had previously undergone mi-
noramputation.Itcanbereasonablysup-
posed that patients with a history of ulcer
may be more aware of the serious conse-
quences of plantar ulcers, and therefore
their compliance might be higher than
that of patients with a ﬁrst ulcer episode.
One could argue that those patients with
recurringulcerswereinherentlylesscom-
pliant because they did, indeed, have a
recurrent ulcer. However, only data on
reulceration outcomes during long-term
follow-up would allow us to draw a rea-
sonable conclusion.
In the study of Ha Van et al. (25), the
presence of a persistent ulcer prompted
clinicians to provide patients with a TCC
rather than an orthopedic cast walker
boot, and patients treated with a TCC
achieved better outcomes. It could be hy-
pothesized that the “persistent ulcer” in
the study of Ha Van et al. might have
played a role similar to that of the “previ-
ous ulcer” in our study. However, this
study, although commonly quoted to
support the importance of patient com-
pliance, was not a randomized clinical
trial. In fact, compliance was taken into
account in choosing the most adequate
off-loadingdeviceforeachpatient.There-
fore, compliance played a critical role in
treatment allocation.
The effectiveness of the Stabil-D ac-
tion in promoting ulcer healing is related
to the ability of the rigid, boat-shaped,
and fully rocker bottom sole to redistrib-
ute most of the pressure from the meta-
tarsal heads to the back foot. Therefore,
the effectiveness of the Stabil-D relates to
pressure redistribution by diverting most
of the pressure from the sole of the foot to
the leg muscles. This is a mechanism dif-
ferent from that of the TCC, which pro-
duces a reduction of mechanical loading.
Asinourstudy,thestudyreportedby
Caravaggi et al. (21) indicated that cast
removability per se does not inﬂuence ul-
cer healing. In contrast to the results of
that study, we did not ﬁnd a difference in
healing time between groups. We specu-
late that this may be due to differences in
device structure.
Distribution of variables did not sig-
niﬁcantlyvarybetweenthetwogroups,as
one would hope to see in a randomized
study. However, better A1C levels, al-
though not statistically signiﬁcant, were
observedintheStabilDgroup.Couldim-
provedglucosecontrolhavepositivelyin-
ﬂuenced patient compliance in general
and, perhaps, the rate of ulcer healing in
Figure 3—Kaplan-Meier estimate of complete healing rate at study completion.
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Onlyfurtherstudiesinlargerpopulations
might resolve this issue.
The results of our study indicate that
pressure off-loading using the Stabil-D
and pressure off-loading using total con-
tact casting are equally effective in the
treatment of neuropathic forefoot plantar
ulcers, thus proving that optimal results
may be obtained with a removable cast
walker. Moreover, considering that the
Stabil-D device is less bulky than a TCC
and therefore may cause fewer sleep
problems, we believe that these results
are also important in terms of patient
qualityoflife.Aboveall,ourresultssug-
gest that more effective options may be
available in the management of neuro-
pathic forefoot plantar ulcers, particu-
larly in centers that do not have the
technology and/or investments avail-
able to provide TCCs.
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